Találati lista | Tudóstér

001-es BibID:	BIBFORM101250
035-os BibID:	(WOS)000789337700001 (Scopus)85129997553
Első szerző:	McInnes, Iain B.
Cím:	A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition / Iain B. McInnes, Zoltán Szekanecz, Dennis McGonagle, Walter P. Maksymowych, Alexander Pfeil, Ralph Lippe, In-Ho Song, Apinya Lertratanakul, Thierry Sornasse, Ana Biljan, Atul Deodhar
Dátum:	2021
ISSN:	1462-0324 1462-0332
Megjegyzések:	Spondyloarthritis (SpA) comprises a group of chronic inflammatory diseases with overlapping clinical, genetic and pathophysiological features including back pain, peripheral arthritis, psoriasis, enthesitis, and dactylitis. Several cytokines are involved in the pathogenesis of SpA, variously contributing to each clinical manifestation. Many SpA-associated cytokines, including interleukin (IL)-23, IL-17, IL-6, type I/II interferon, and tumour necrosis factor signal directly or indirectly via the Janus kinase (JAK)-signal transducer and activator of transcription pathway. JAK signalling also regulates development and maturation of cells of the innate and adaptive immune systems. Accordingly, disruption of this signalling pathway by small molecule oral JAK inhibitors can inhibit signalling implicated in SpA pathogenesis. Herein we discuss the role of JAK signalling in the pathogenesis of SpA and summarise the safety and efficacy of JAK inhibition via reference to relevant SpA clinical trials.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk Janus kinase inhibitor ankylosing spondylitis psoriatic arthritis spondyloarthritis
Megjelenés:	Rheumatology. - 61 : 5 (2021), p. 1783-1794. -
További szerzők:	Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) McGonagle, Dennis Maksymowych, Walter P. Pfeil, Alexander Lippe, Ralph Song, In-Ho Lertratanakul, Apinya Sornasse, Thierry Biljan, Ana Deodhar, Atul
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM114359
035-os BibID:	(WoS)001065800700001 (Scopus)85179996474
Első szerző:	Taylor, Peter C.
Cím:	Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases / Peter C. Taylor, Ernest Choy, Xenofon Baraliakos, Zoltan Szekanecz, Ricardo M. Xavier, John D. Isaacs, Sander Strengholt, Julie M. Parmentier, Ralph Lippe, Yoshiya Tanaka
Dátum:	2024
ISSN:	1462-0324 1462-0332
Megjegyzések:	Janus kinases (JAKs) are a family of cytosolic tyrosine kinases that regulate cytokine signal transduction, including cytokines involved in a range of inflammatory diseases, such as RA, psoriasis, atopic dermatitis and IBD. Several small-molecule JAK inhibitors (JAKis) are now approved for the treatment of various immune-mediated inflammatory diseases. There are, however, key differences between these agents that could potentially translate into unique clinical profiles. Each JAKi has a unique chemical structure, resulting in a distinctive mode of binding within the catalytic cleft of the target JAK, and giving rise to distinct pharmacological characteristics. In addition, the available agents have differing selectivity for JAK isoforms, as well as off-target effects against non-JAKs. Other differences include effects on haematological parameters, DNA damage repair, reproductive toxicity and metabolism/elimination. Here we review the pharmacological profiles of the JAKis abrocitinib, baricitinib, filgotinib, peficitinib, tofacitinib and upadacitinib.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Rheumatology. - 63 : 2 (2024), p. 298-308. -
További szerzők:	Choy, Ernest Baraliakos, Xenofon Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Xavier, Ricardo M. Isaacs, John D. Strengholt, Sander Parmentier, Julie M. Lippe, Ralph Tanaka, Yoshiya
Internet cím:	DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: